Table 1.

Status and indication of drugs currently in clinical trials that target molecules involved in cell migration.

Target	Drugsa)	Company	Indicationb)	Status
CCR1
	BX471	Schering AG/Berlex	Pelvic pain	Phase 2 completed
	CCX354	ChemoCentryx	RA	Phase 2 completed
	AZD-4818	AstraZeneca	COPD	Phase 2 completed
CCR2
	PF-04634817	Pfizer	Diabetic Nephropathy	Phase 2 recruiting
	PF-04136309	Pfizer	Osteoarthritis Pancreatic cancer	Phase 2 completed Phase 1 recruiting
	MK-0812	Merk	MS RA	Phase 2 completed Phase 2 failed
	CCX-140	ChemoCentryx	Diabetic Nephropathy	Phase 2 recruiting
	CNTO-888	Centocor	IPF	Phase 2 completed
CCR3
	Bertilimumab	Cambridge Antibody Technology	UC	Phase 2 planned
	GW766944	GlaxoSmithKline	Asthma	Phase 2 completed
CCR4
	AMG-761	Amgen	Asthma	Phase 1 recruiting
CCR5
	Maraviroc	Pfizer	HIV, immune reconstitution	Active
	GSK706769	GlaxoSmithKline	RA	Phase 2 withdrawn
	HGS1025	GlaxoSmithKline	UC	Phase 1 withdrawn
CCR9
	GSK 1605786A	GlaxoSmithKline	UC	Phase 3 recruiting
	CCX282-B	ChemoCentryx	UC Crohn’s Celiac	Phase 2 completed Phase 2 completed Phase 2 completed
CXCR2
	GSK 1325756	GlaxoSmithKline	COPD	Phase 1 completed
	SB-6569333-AAA	GlaxoSmithKline	COPD CF	Phase 1 completed Phase 1 completed
CXCR3
	MSX1100	Bristol-Meyer Squibb	RA UC	Phase 2 completed Phase 2 completed
CXCR1/CXCR2
	SCH 527123	Schering-Plough	Psoriasis Asthma COPD	Phase 2 completed Phase 2 completed Phase 2 completed
CRTH2
	ARRY-502	Array BioPharma	Asthma	Phase 2 recruiting
	QAV680	Novartis	Allergic Rhinitis	Phase 2 completed
	QAW039	Novartis	Asthma	Phase 2 recruiting
	ADC3680B	Pulmagen Therapeutics	Asthma	Phase 2 completed
CRTH2 and DP1
	AMG 853	Amgen	Asthma	Phase 2 completed
LTB4
	CP-195543	Pfizer	RA	Phase 2 terminated
	BIIL-284	Boehringer Ingelheim	CF	Phase 2 terminated
S1P1
	GSK 2018682	GlaxoSmithKline	MS	Phase 1 completed
	ACT-128800	Actelion	MS Psoriasis	Phase 2 ongoing Phase 2 completed
Selectins (E,P,L)
	Bimosiamose	Revotar	COPD Psoriasis	Phase 2 completed Phase 2 completed
Integrin α4β7
	Vedolizumab	Millennium	Crohn’s UC	Phase 3 completed Phase 3 ongoing
	AMG 181	Amgen	UC	Phase 2 planned
Integrin αLβ2
	BMS-587101	Bristol-Meyers Squibb	Psoriasis	Phase 2 terminated
	MIRT 2584	Boehringer Ingelheim	Psoriasis	Phase 2 suspended

^a) This table does not list all compounds currently in development but instead summarizes drugs targeting the indicated molecules that are listed on www.clinicaltrials.gov.

^b) RA: rheumatoid arthritis, COPD: chronic obstructive pulmonary disease, MS: multiple sclerosis, IPF: idiopathic pulmonary fibrosis, UC: ulcerative colitis, HIV: human immunodeficiency virus, CF: cystic fibrosis, SIP1: sphingosine-1 phosphate receptor subtype 1.